found in secretions and body fluids, and exhibit size heterogeneity upon purification, as discussed above. Based on these observations, it is likely that many glycosyltransferases share a common domain structure with the sialyltransferase.
What is the basis for the subcellular localization of the glycosyltransferases? It has been demonstrated that the fi-galactoside a2,6-sialyltransferase is localized to the trans region of the Golgi apparatus stack in hepatocytes and in intestinal goblet cells, and is found throughout the Golgi apparatus of intestinal absorptive cells (Roth et al., 1985; 1986) . Inspection of the sequence provides few clues as to the polypeptide domains which encode the information mediating subcellular localization. It is unlikely that the soluble catalytic domain found in secretions would determine localization. Probable candidates would include the cytoplasmic domain, the trans-membrane domain and the polypeptide sequences close to the lumenal side of the membrane. Now that a cDNA containing the complete coding sequence of the sialyltransferase has been obtained, it should be possible to carry out a systematic investigation of the molecular basis of the localization of the sialyltransferase within the Golgi apparatus of cells through the use of eukaryotic expression vectors and site-directed mutagenesis.
The antigens associated with the human ABO, H and Lewis blood group systems were the first mammalian glycoconjugates to be studied in terms of the genetic control of their biosynthesis. Systematic immunochemical investigations of the antigens began in the 194Os, and workers entering this field had the advantage that the ABO system had earlier been subjected to rigorous formal genetic analysis (see Race & Sanger, 1975) . The unambiguous patterns of inheritance of the antigens made it apparent that their biosynthesis must be under some form of strict genetic regulation. The immunological properties that had provided markers for genetic analysis also afforded sensitive indicators for detecting changes in the antigens when they were subjected to chemical or enzymic degradation. Detailed immunochemical studies established that the antigenic determinants are carbohydrate (Morgan, 1960; Kabat, 1970; Watkins, 1972) and are therefore not the primary translated products of the blood group genes. The question that then arose was how complex heterosaccharide structures are assembled with high fidelity in the absence of a template. A number of different glycosyltransferases are required to synthesize a single oligosaccharide chain, and, in general, each enzyme will be encoded by a different gene. This paper will briefly summarize the work that led to a solution to this problem and will then pose some of the questions relating to the blood group loci that still remain unanswered.
Epithelial-type glycoproteins purified from ovarian cyst fluids, obtained from individual patients of known blood group, were the materials used for the isolation and structural characterization of the A, B, H, Lea and Leh determinants (Morgan, 1960; Morgan & Watkins, 1969) (Table I ). In these secreted glycoproteins the A, B and H determinants are associated with three types of chain ending, Type I (Galfil-3GlcNAc), Type 2 (GalflI-4GlcNAc) and Type 3 (Galfil-3GalNAc) (Rege et al., 1963; Rovis et al., 1973; Donald, 1981) . Lewis Lea and Leh active structures are found only on Type 1 chains but the corresponding monoand di-fucosylated Type 2 structures, now called X and Y (Table I) , also occur as terminal non-reducing structures in the glycoproteins (Marr et a[., 1968; Lloyd et al., 1968) . The same A, B and H determinant groups were subsequently identified on the erythrocyte membrane as components of both glycosphingolipids (Koscielak, 1977; Hakomori et al., 1977) and glycoproteins (Finne et al., 1980) . Lea and Leh determinants are also present on the erythrocyte surface as part of glycosphingolipid molecules but they are taken up from the plasma in which the cells circulate and are not integral components of the membranes (Marcus & Cass, 1969) . Until recently, the A, B and H active groupings on both the integral glycosphingolipids and glycoproteins were thought to be carried only on Type 2 precursor oligosaccharide chains but the isolation from erythrocytes of two unusual glycosphingolipids, the so-called 'repetitive A' 621st MEETING, LONDON 
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based on a Type 3 (Galpl-3GalNAca-R) structure (Clausen et al., 1985) and 'globo-A' based on a previously unencountered Type 4 precursor structure (GalPI-3GalNAcfl-R), (Clausen et al., 1984) , indicate that other precursors may be utilized at the site of synthesis of the erythrocyte antigens. These findings are of importance in relation to the specificities of the glycosyltransferases that are assumed to be expressed in haemopoietic tissue. In our laboratory the culmination of the first phase of the work on the primary structural identification of the oligosaccharides responsible for blood group activity came with the isolation of the Leb determinant (Marr et al., 1967) . This was the first example of a carbohydrate antigen arising from the interaction of two distinct genes ( H and Le) to be structurally characterized and it clearly demonstrated that the tenet of 'one gene-one antigen' was not applicable to carbohydrate antigens. Once the nature of the determinants was established we turned our attention to the enzymes involved in their biosynthesis. Sequential degradation of human ABH and Lewis blood group specific glycoproteins with exoglycosidases had revealed that removal of a single terminal non-reducing sugar resulted in the loss of the original antigenic property and the development of a new specificity (Watkins, 1962) . The demonstration that each carbohydrate structure is masked by the addition of a single monosaccharide unit suggested that biosynthesis proceeds Vol. 15 by a reversal of the degradation pathways and it was therefore proposed that the blood group genes encode the glycosyltransferases that catalyse the addition of the monosaccharides that complete the biosynthesis of the antigenic structures (Watkins & Morgan, 1959; Watkins, 1967) . However, although the terminal non-reducing sugar was seen to play a vital role in the determination of a particular specificity, oligosaccharide inhibition experiments (Watkins & Morgan, 1962; Schiffman et al., 1964) clearly demonstrated that the combining sites of the blood group antibodies correspond to at least a trisaccharide and, in some instances, to larger oligosaccharide structures, and it was apparent that biosynthesis of the blood group antigens could not result from a random addition of monosaccharide units. Hence the product of one transfer reaction was inferred to be the preferred substrate for the next glycosyltransferase in the series. The stringent specificity of glycosyltransferases is now known to be one of their most striking features (reviewed in Schachter, 1978; Beyer et al., 1981; Berger et al., 1982) and the precise requirement for the correct acceptor substance allows for accurate reproduction of complex heterosaccharide structures.
Experimental verification of occurrence of the predicted glycosyltransferases in blood and tissue from donors of known blood group and secretor status (reviewed in Ginsburg, 1972; Watkins, 1972) opened up a new phase for the further genetic analysis of the subgroups and rare variants in the ABO and Lewis systems and for fundamental investigations on the gene-encoded enzymes. Unlike most other enzyme polymorphisms, weakness or failure of expression of the enzymes encoded at the ABO. H or Le loci does not appear to be associated with disease or disability. In the ABO system especially, serologists have identified a wide variety of serological variants (Race & Sanger, 1975) and studies on the enzymic basis of these rare phenotypes has revealed a number of mutant forms of the transferases differing in pH optimum,, K,,, values for acceptor or donor substrates or in maximum velocity. These forms are usually less efficient at transferring their respective sugars and hence lead to weakened serological expression of the antigens (examples reviewed in Salmon & Cartron, 1977; Watkins, 1980) . Absence or weak expression of the H-gene-associated cc-2-~-fucosyltransferase has been established as the basis of the rare 'Bombay' phenotypes in which A, B and H antigens are missing from erythrocytes and absence of the same enzyme activity from epithelial tissues has also been shown to constitute the basis of the non-secretor phenotype. As genetic markers the transferases have also made a contribution to an understanding of human twin and dispermic chimaeras and to the rare cis AB phenotype in which both A and B characters are inherited from one parent (see Watkins, 1980) . Investigations on AB heterozygotes has confirmed that the A and B genes are co-dominant as far as the expression of the glycosyltransferases are concerned, but may assume dominance over each other at the level of expression of the antigens because the enzymes compete for the same acceptor substrate with suppression of expression of either A or B antigenic activity (Greenwell & Watkins, 1982; Yoshida, 1983; Fredrick et al., 1985) .
The blood-group-gene-associated glycosyltransferases have contributed not only to the studies on the enzymic basis of normal and rare ABO and Lewis phenotypes but also to the general body of knowledge on these sugartransferring enzymes. The precision of specificity of glycosyltransferases for both acceptor and donor substrates in general supports the concept first put forward by Hagopian & Eylar ( 1 968) of one enzyme-one glycosidic linkage. This concept, when coupled with the 'one gene-one enzyme' hypothesis derived from the classical work of Garrod, Bateson, Beadle and Tatum, suggests that one gene is ultimately responsible for the biosynthesis of one glycosidic linkage. It is now known, however, that despite the clear cut serological distinctions between the blood groups, the B-gene-associated cc-3-~-galactosyltransferase has the capacity to transfer N-acetyl-D-galactosamine to make A determinants (Greenwell et al., 1979) and the A-gene-associated cc-3-N-acetyl-~-galactosaminyltransferase has the capacity to make B determinants (Yates & Watkins, 1982) . Thus both enzymes have the potential to make A and B antigenic structures although in vastly different amounts. This overlapping function is not surprising in view of the allelic status of the A and B genes but it does mean the 'one gene-one glycosidic linkage' rule cannot be taken as absolute. The Lewis blood group system provides another example of a seemingly anomalous glycosyltransferase. An cc-L-fucosyltransferase present only in those individuals carrying an Le gene appears to transfer fucose to both the 0 -4 position of subterminal N-acetylglucosamine residues to form Led and Leh structures and to the 0-3 position of D-glucose in lactose and milk oligosaccharides (Johnson et al., 1981; Prieels er d., 1981) . If these are indeed the activities of a single enzyme this represents the first example of a glycosyltransferase utilizing two different acceptor sugars and adding the donor sugar to different positions in these acceptor molecules.
Although the blood group antigens associated with the ABO, Hh and Lele loci are the best-studied examples in mammalian genetics of gene-controlled biosynthesis of oligosaccharides, many questions remain unanswered. The ABO locus has been mapped to the distal end of the long arm of human chromosome 9 (9q33-qter) (Rapley et al., 1968; Ferguson-Smith et a/., 1976) by means of its linkage to the loci for nail patella syndrome and adenylate kinase. However, the expression of the A-gene-and B-geneassociated transferases has not yet been shown unequivocally to be controlled by the locus on chromosome 9. Direct tests for A and B transferase activities in humanrodent somatic cell hybrids, with and without human chromosome 9, could perhaps provide an answer to this question. In the absence of such direct confirmation we cannot rule out the possibility that the locus on chromosome 9 is regulating the expression of ubiquitous glycosyltransferases encoded by genes on other chromosomes. Another approach to this problem is that of cloning the genes for the transferases and testing for hybridization to Southern transfers of DNA from the human-rodent somatic cell hybrids or for hybridization in situ with chromosome 9 preparations. This approach is just now being explored (Greenwell et al., 1987) and opens up a third phase of the work on the blood group antigens in which the emphasis will shift from the enzymology of the glycosyltransferases to the structure and regulation of the genes. If by any chance probes identified as detecting the DNA encoding the A or B transferases do not map to chromosome 9 we will know that the ultimate goal of tracing the pathway from the antigens to the blood group genes has not yet been reached. In the discussions so far it has been assumed that A and B are alleles at the ABO locus and that their products are respectively an cc-3-N-acetyl-~-galactosaminyltransferase and an a-3-~-galactosyltransferase. However, amongst the mammalian genetic systems investigated until now the ABO locus is the only one for which it has been proposed that the alleles encode enzymes with qualitatively different specificities. In general, the products of allelic genes show quantitative variations in biochemical behaviour and the difference in specificity, together with the appearance of A antigen in cancerous tissues of group B patients (e.g. Hakkinen, 1970) , has led some geneticists to doubt the allelic status of A and B (Boettcher, 1978) . Considered from the point of view of the structures of the sugars transferred by the glycosyltransferases the specificities of the two enzymes can in fact be seen to be very similar, since each catalyses the transfer of a monosaccharide with basically a D-galactose configuration to the same acceptor substrate. However, one could speculate that genes encoding enzymes with similar, but not identical, specificities might arise by duplication, followed by mutations in one of the gene pair leading to the sequence change necessary to switch the enzyme specificity. The availability of cDNA probes for the enzymes will allow these various possibilities to be explored and sequence studies on the DNA should reveal the extent of alteration in base composition of the DNA, and hence of the amino acid composition of the protein, necessary to change the specificity of a glycosyltransferase from one catalysing the transfer of D-galactose to one catalysing the transfer of N-acetylgalactosamine.
The third allele 0 at the ABO locus does not give rise to an antigenically active structure analogous to the blood group A and B antigens and it is still not clear whether the gene encodes an enzymically inactive protein structurally related to the A-gene-and B-gene-associated glycosyltransferases. Theoretically one might expect many different 0 genes to have arisen from mutations in A or B genes that rendered their products enzymically inactive. The status of the 0 allele is another question to which the answer should be forthcoming when genetic probes are available for the A and B transferases.
In spite of the detailed serological, genetical and immunochemical studies carried out on the ABO blood group system it has not proved possible to assign a function to the antigens or to determine the selective pressures that maintain the polymorphism. The epithelial glycoproteins carrying blood group specificities undoubtedly have a function as constituents of the mucin that protects and lubricates mucosal surfaces, but the carbohydrate structures conferring the blood group activity cannot themselves be fulfilling an essential physiological role because the absence of any one blood group character does not result in a pathological condition. Recently, Koscielak (1986) advanced the theory that the A, B, H and Lewis structures confer biological inertness on otherwise functionally active carbohydrate structures; since the determinants are the end-structures on the oligosaccharide chains in circulating glycoproteins, and on fully differentiated cells that are destined to survive in vivo, such a role appears feasible. However, an explanation is still required to account for the maintenance of the polymorphism at the ABO locus, since both D-gakiCtOSyl and N-acetyl-D-galactosaminyl residues would presumably function equally well in masking the underlying structures. It has been suggested by a number of authors that the key to this puzzle lies with the relationship of the blood group antigens to bacterial polysaccharides, or to the differential adherence of micro-organisms to the blood group determinants. The part played by these relationships in the balanced polymorphism of the ABO locus has, however, still to be proven. An area of glycoconjugate biosynthesis which has not yet been greatly explored is the regulation of glycosyltransferase expression. The enzymes associated with ABO, H and Lewis blood groups are good potential candidates for the study of regulation because they are not expressed in all tissues and the pattern of expression is not the same in all individuals. Earlier studies on blood group antigen expression were carried out on the two readily available body fluids, blood and saliva. It was noted that ABH antigens could occur in soluble form in saliva but not all individuals who express ABH antigens on their red cells had ABH activity in their saliva. A secretor gene, Se, was invoked as the agent controlling the capacity to secrete active substances (see Race & Sanger, 1975) . The role of the Se gene was for many years considered to be that of a regulator or switch gene which controls the expression of the H gene in epithelial tissues (Watkins, 1980) but more recently Oriol et al. (1981) proposed that there are two structural genes encoding tl-2-~-fucosyltransferases, the H gene, expressed in tissues of mesodermal origin, which encodes an enzyme reacting preferentially with Type 2 chain precursors, and the Se gene, expressed in epithelial tissue, which encodes an enzyme reacting preferentially with Type 1 chain precursors. These predictions provided a stimulus for more detailed studies on the distribution and specificity of cr-2-~-fucosyltransferase activity and several laboratories have now confirmed that enzyme species with preferences for Type 1 or Type 2 chains do indeed exist in different tissues (Le Pendu, 1983; Kumazaki & Yoshida, 1984; Betteridge & Watkins, 1985) . The interpretation that Se is a structural gene is now widely accepted but other explanations such as tissue-specific posttranslational modifications of an H gene product have not yet been ruled out. Immunofluorescent studies with monoclonal antibodies on the distribution of Types 1, 2, 3 and 4
A and H determinants in various tissues indicate that other parameters than the embryological origin of the tissues must contribute to the final picture (Oriol et al., 1986) . The activities appearing in different tissues also suggest that interpretation of whether or not an individual carries a particular Vol. 15 gene in the genome may be an oversimplification if it is based solely on results of studies on erythrocytes and saliva.
Many other questions could be posed in relation to the genetic regulation of glycoconjugate expression to which the rapidly expanding techniques of molecular genetics will undoubtedly provide an answer. If 1 may end on a personal note, I can confirm, as one who has had the good fortune to be associated with various aspects of the biochemical genetics of blood group antigens since the 1940s, that this fascinating field never ceases to present new challenges. As each layer is peeled away another is revealed and the skills and background knowledge required are constantly changing. For me the excitement, stimulus and dilemma of this type of work are most aptly summarized by Mark Pattison in his biography of Isaac Casaubon written in 1875:
In research the horizon recedes as we advance and is no nearer at sixty than it was at twenty. As the power of endurance weakens with age the urgency of the pursuit grows more intense . . . And research is always incomplete
